Rabies Vaccine Market - Growth, Trends, and Forecast (2019 - 2024)

The market is segmented by product type, vaccination type (Pre-Exposure Vaccination (PEV), and Post-Exposure Prophylaxis (PEP)), end-user, and geography.

Market Snapshot

rabies vaccine market image 1
Study Period:

2016-2024

Base Year:

2018

Fastest Growing Market:

Asia Pacific

Largest Market:

North America

CAGR:

5.0%

Key Players:

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Market Overview

Rabies is a viral disease spread by the bite or scratch of an animal, however, the symptoms appear relatively slowly. In such cases, by the time, the symptoms appear, it is generally too late to save the patients. In the developed markets, the cases of human rabies is less because of more pet firendly communities and government initiatives, however, in emerging markets as well as low-income countries, there are fewer regulations to protect the people against animals bites and a large number of stray dogs can be observed across metropolitan cities as well as other cities and towns. Such factors raise the concerns regarding low protection against dog bites which raises the demand of rabies vaccines in such regions. However, limited resources, as well as negligence by government general public, are among the major causes which limit the use and adoption of rabies vaccines.

Scope of the Report

Domestic dogs are among the most common reservoir of viruses, which is regaulalry being check ed by government initiatives adopted well across major cities and region in the world. However, still, several diagnosis tests and vaccines are given to prevent the caases of rabies across humans. The scope of the report cover the rabies vaccines market by product, vaccination type, end-user and geography.

By Product Type
Baby Hamster Kidney (BHK)
Purified Chick Embryo Cell Rabies Vaccine
Vero Cell Rabies Vaccine
Other Product Types
By Vaccination Type
Pre-Exposure Vaccination (PEV)
Post-Exposure Prophylaxis (PEP)
By End User
Animals
Humans
Geography
North America
United States
Canada
Mexico
Europe
France
Germany
United Kingdom
Italy
Spain
Rest of Europe
Asia Pacific
China
Japan
India
Australia
South Korea
Rest of Asia-Pacific
Middle East and Africa
GCC
South Africa
Rest of Middle East and Africa
South America
Brazil
Argentina
Rest of South America

Report scope can be customized per your requirements. Click here.

Key Market Trends

The Purified Chick Embryo Cell Rabies Vaccine is Estimated to Contribute Large, Over the Forecast Period

The purified chick embryo cell vaccine is used to protect people from post-exposure or pre-exposure. The veterinarians who are in contact with animals, such as cats, dogs, foxes, skunks, raccoons, bobcats, coyotes, and bats are more likely to be exposed to the rabies virus. Purified chick embryo cell rabies vaccines are prepared with the help of primary chick embryo cells derived from specific pathogen-free (SPF) eggs. It consists of purified and concentrated rabies virus antigen, inactivated with B-propiolactone. This vaccine acts by exposing a small dose of rabies virus to the patient in order to develop immunity to the disease. This vaccine can be used for post-exposure or pre-exposure. Such factors drive its importance and usage across hospitals and clinics.

rabies vaccine market image 2

To understand key trends, Download Sample Report

North America is Estimated to Have Largest Share in the Global Market

According to the data published by Centers for Disease Control and Prevention (CDC) in the United States, wild animals accounted for 92.4% of the rabies cases, whereas domestic animals accounted for 48.7% cases of rabies in 2015. In the past few years the number of human deaths attributed to rabies in the United States has declined due to two major reasons, first one is animal control and vaccination programs. Secondly, effective human rabies vaccines and immunoglobulins have been developed over time. Similarly major steps were taken across Canada and Mexico to protect the animals and humans rabies virus infection spread. Significant contribution by government and companies interests in this regions, makes this region, highly useful in terms of demand and use of rabies vaccines.

rabies vaccine market image 3

To understand geography trends, Download Sample Report

Competitive Landscape

The major market players are focusing on technological advancements and pet care initiatives in collabroation with hospitals and government channels. Some of the major players in the market are AstraZeneca (MedImmune), GlaxoSmithKline, Merck & Co Inc, Sanofi Pasteur, Inc, and Cadila Pharmaceuticals Ltd, among others.

Major Players

  1. AstraZeneca (MedImmune)
  2. GlaxoSmithKline PLC
  3. Merck & Co., Inc
  4. Sanofi Pasteur Limited
  5. Zoetis Animal Healthcare

* Complete list of players covered available in the table of contents below

rabies vaccine market image 5

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Deliverables

    2. 1.2 Study Assumptions

    3. 1.3 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

      1. 4.2.1 Growing Burden of Mortality due to Rabies

      2. 4.2.2 Large Population of Stray Dogs in Low and Middle Income Countries

      3. 4.2.3 Growing Pet Management technological Advancements and Services

    3. 4.3 Market Restraints

      1. 4.3.1 Low Immunization Rates in Dogs

      2. 4.3.2 Lack of Awareness and Negligence by Government and Public

    4. 4.4 Porter's Five Force Analysis

      1. 4.4.1 Threat of New Entrants

      2. 4.4.2 Bargaining Power of Buyers/Consumers

      3. 4.4.3 Bargaining Power of Suppliers

      4. 4.4.4 Threat of Substitute Products

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product Type

      1. 5.1.1 Baby Hamster Kidney (BHK)

      2. 5.1.2 Purified Chick Embryo Cell Rabies Vaccine

      3. 5.1.3 Vero Cell Rabies Vaccine

      4. 5.1.4 Other Product Types

    2. 5.2 By Vaccination Type

      1. 5.2.1 Pre-Exposure Vaccination (PEV)

      2. 5.2.2 Post-Exposure Prophylaxis (PEP)

    3. 5.3 By End User

      1. 5.3.1 Animals

      2. 5.3.2 Humans

    4. 5.4 Geography

      1. 5.4.1 North America

        1. 5.4.1.1 United States

        2. 5.4.1.2 Canada

        3. 5.4.1.3 Mexico

      2. 5.4.2 Europe

        1. 5.4.2.1 France

        2. 5.4.2.2 Germany

        3. 5.4.2.3 United Kingdom

        4. 5.4.2.4 Italy

        5. 5.4.2.5 Spain

        6. 5.4.2.6 Rest of Europe

      3. 5.4.3 Asia Pacific

        1. 5.4.3.1 China

        2. 5.4.3.2 Japan

        3. 5.4.3.3 India

        4. 5.4.3.4 Australia

        5. 5.4.3.5 South Korea

        6. 5.4.3.6 Rest of Asia-Pacific

      4. 5.4.4 Middle East and Africa

        1. 5.4.4.1 GCC

        2. 5.4.4.2 South Africa

        3. 5.4.4.3 Rest of Middle East and Africa

      5. 5.4.5 South America

        1. 5.4.5.1 Brazil

        2. 5.4.5.2 Argentina

        3. 5.4.5.3 Rest of South America

  6. 6. COMPETITIVE LANDSCAPE

    1. 6.1 Company Profiles

      1. 6.1.1 AstraZeneca (MedImmune)

      2. 6.1.2 Berna Biotech Ltd

      3. 6.1.3 GlaxoSmithKline

      4. 6.1.4 Merck & Co Inc

      5. 6.1.5 Novartis AG

      6. 6.1.6 Pfizer Inc

      7. 6.1.7 Sanofi Pasteur, Inc

      8. 6.1.8 Zoetis Animal Healthcare

      9. 6.1.9 * List Not Exhaustive

    2. *List Not Exhaustive
  7. 7. MARKET OPPORTUNITIES AND FUTURE TRENDS

**Competitive Landscape covers- Business Overview, Financials, Products and Strategies and Recent Developments

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please Enter a Valid Message!


Complete your payment details below

Shipping & Billing Information

Payment Information